Skip to contentW
Windtree Therapeutics Inc
W
WINTWindtree Therapeutics Inc Q2 2018 · 10-Q
Revenue$1.05M$1.05M−8.4% vs Q2 2017 Net Income-$3.05M-$3.05MN/M vs Q2 2017 EPS Diluted-$0.81-$0.81N/M vs Q2 2017 Operating Income-$3,036,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Windtree Therapeutics Inc · CIK 946486 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-288.9%+246.4 pt vs Q2 2017
Net margin-290.4%+298.3 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 14, 2018 · 45 d after period end